^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-A3055

    i
    Associations
    News

    Trials

    Company:
    BeiGene
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (NCT05935098)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    08/21/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    CCR8
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055